Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 4/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748413 | 0.90 | HDAC2 (0.48) | HDAC2HDAC1MMP13PTPN2PTPN1 | |
| SCHEMBL21361249 | 0.87 | HDAC2 (0.38) | HDAC2HDAC1 | |
| SCHEMBL21361289 | 0.86 | HDAC2 (0.42) | HDAC2HDAC1MEN1KMT2A | |
| SCHEMBL21344641 | 0.85 | ACACB (0.42) | HDAC2HDAC1GPR119MEN1KMT2A | |
| SCHEMBL21361255 | 0.84 | HDAC2 (0.42) | HDAC2HDAC1 | |
| SCHEMBL21285092 | 0.83 | GPR119 (0.42) | HDAC2HDAC1GPR119ACACB | |
| SCHEMBL21361254 | 0.83 | RORC (0.40) | HDAC2HDAC1MEN1KMT2A | |
| SCHEMBL21361248 | 0.83 | HDAC2 (0.37) | HDAC2HDAC1 | |
| SCHEMBL21361252 | 0.83 | HDAC2 (0.41) | HDAC2HDAC1 | |
| SCHEMBL21361246 | 0.82 | CYP3A4 (0.47) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765445-B1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| US-20210000113-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-01-07 | — | — | US | disclosed |
| WO-2019175117-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000113-A1 | SPIRO CYCLOHEXANEDIONE DERIVATES AS HERBICIDES | CBR3, DDT, CBR1 | HDAC2 964/4885HDAC1 845/4885MMP13 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.